Re-evaluation of cellular radiosensitization by 5-fluorouracil: High-dose, pulsed administration is effective and preferable to conventional low-dose, chronic administration

References

• Aschele C, Guglielmi A, Tixi LM, Bolli E, Mori AM, Lionetto R, Rosso R, Sobrero A. 1995. Adjuvant treatment of colorectal cancer in the elderly. Cancer Control 2:S36–38.
   PubMedGoogle Scholar
• Boothman DA, Davis TW, Sahijdak WM. 1994. Enhanced expression of thymidine kinase in human cells following ionizing radiation. International Journal of Radiation Oncology Biology Physics 30: 391–398.
   PubMed Web of Science ®Google Scholar
• Boothman DA, Meyers M, Fukunaga N, Lee SW. 1993. Isolation of x-ray-inducible transcripts from radioresistant human melanoma cells. Proceedings of the National Academy of Sciences of the USA 90:7200–7204.
   PubMed Web of Science ®Google Scholar
• Borner M, Scheithauer W, Twelves C, Maroun J, Wilke H. 2001. Answering patients’ needs: Oral alternatives to intravenous therapy. Oncologist 6:S12–16.
   PubMed Web of Science ®Google Scholar
• Borner MM, Schoffski P, de Wit R, Caponigro F, Comella G, Sulkes A, Greim G, Peters GJ, van der Born K, Wanders J, et al. 2002. Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: A randomised crossover trial in advanced colorectal cancer. European Journal of Cancer 38:349–358.
   PubMed Web of Science ®Google Scholar
• Bunz F, Hwang PM, Torrance C, Waldman T, Zhang Y, Dillehay L, Williams J, Lengauer C, Kinzler KW, Vogelstein B. 1999. Disruption of p53 in human cancer cells alters the responses to therapeutic agents. Journal of Clinical Investigation 104:263–269.
   PubMed Web of Science ®Google Scholar
• Byfield JE. 1989. 5-Fluorouracil radiation sensitization – a brief review. Investigational New Drugs 7:111–116.
   PubMedGoogle Scholar
• Byfield JE, Calabro-Jones P, Klisak I, Kulhanian F. 1982. Pharmacologic requirements for obtaining sensitization of human tumor cells in vitro to combined 5-Fluorouracil or ftorafur and X rays. International Journal of Radiation Oncology Biology Physics 8: 1923–1933.
   PubMed Web of Science ®Google Scholar
• Carlomagno C, Lauria R, De Laurentiis M, Arpino G, Massarelli E, Ferrara C, Milano A, Vernaglia Lombardi A, Costanzo R, Catalano G, et al. 2002. Second-line chemotherapy with a hybrid-alternating regimen of bolus 5FU modulated by methotrexate and infusional 5FU modulated by folinic acid in patients with metastatic colorectal cancer pretreated with 5FU. A phase 2 study. Oncology 63:219–225.
   PubMedGoogle Scholar
• Chapman TR, Kinsella TJ. 2011. Ribonucleotide reductase inhibitors: A new look at an old target for radiosensitization. Frontiers in Oncology 1:56.
   PubMedGoogle Scholar
• Clarkson B, O’Connor A, Winston L, Hutchison D. 1964. The physiologic disposition of 5-Fluorouracil and 5-Fluoro-2′-deoxyuridine in man. Clinical Pharmacology and Therapeutics 5:581–610.
   PubMed Web of Science ®Google Scholar
• Collins JM, Dedrick RL, King FG, Speyer JL, Myers CE. 1980. Nonlinear pharmacokinetic models for 5-fluorouracil in man: Intravenous and intraperitoneal routes. Clinical Pharmacology and Therapeutics 28:235–246.
   PubMed Web of Science ®Google Scholar
• Denehy TR, Eastman R, SanFilippo L, Gregori CA, Breen JL. 1996. Bolus mitomycin C and 5-FU with sequential radiation for poor-prognosis locally advanced cervical cancer. Gynecologic Oncology 60:64–71.
   PubMedGoogle Scholar
• Einhorn LH. 1989. Improvements in fluorouracil chemotherapy?Journal of Clinical Oncology 7:1377–1379.
   PubMedGoogle Scholar
• Elkind MM, Sutton H. 1960. Radiation response of mammalian cells grown in culture. 1. Repair of X-ray damage in surviving Chinese hamster cells. Radiatian Research 13:556–593.
   Google Scholar
• Evans RM, Laskin JD, Hakala MT. 1980. Assessment of growth-limiting events caused by 5-fluorouracil in mouse cells and in human cells. Cancer Research 40:4113–4122.
   PubMedGoogle Scholar
• Fraile RJ, Baker LH, Buroker TR, Horwitz J, Vaitkevicius VK. 1980. Pharmacokinetics of 5-fluorouracil administered orally, by rapid intravenous and by slow infusion. Cancer Research 40:2223–2228.
   PubMed Web of Science ®Google Scholar
• Fukushima M, Fujioka A, Uchida J, Nakagawa F, Takechi T. 2001. Thymidylate synthase (TS) and ribonucleotide reductase (RNR) may be involved in acquired resistance to 5-fluorouracil (5-FU) in human cancer xenografts in vivo. European Journal of Cancer and Clinical Oncology 37:1681–1687.
   Google Scholar
• Gastrointestinal Tumor Study Group. 1985. Prolongation of the disease-free interval in surgically treated rectal carcinoma. New England Journal of Medicine 312:1465–1472.
   PubMed Web of Science ®Google Scholar
• Gunderson LL. 1986. Perineal irradiation for rectal cancer?International Journal of Radiation Oncology Biology Physics 12:283–284.
   PubMedGoogle Scholar
• Gunderson LL, Collins R, Earle JD, Moertel CK, Krook J, Martenson J. 1986. Adjuvant treatment of rectal cancer: Randomized prospective study of irradiation +/− chemotherapy: A NCCTG study. International Journal of Radiation Oncology Biology Physics 12:169.
   Google Scholar
• He Q, Skog S, Welander I, Tribukait B. 2002. X-irradiation effects on thymidine kinase (TK): I. TK1 and 2 in normal and malignant cells. Cell Proliferation 35:69–81.
   PubMedGoogle Scholar
• Heidelberger C, Baumann ME. 1957. Studies on OPSPA. I. The effect of several phosphoramides on transplanted tumors. Cancer Research 17:277–283.
   Google Scholar
• Heidelberger C, Griesbach L, Montag BJ, Mooren D, Cruz O, Schnitzer RJ, Grunberg E. 1958. Studies on fluorinated pyrimidines. II. Effects on transplanted tumors. Cancer Research 18:305–317.
   PubMed Web of Science ®Google Scholar
• Herrmann R, Knuth A, Kleeberg U, Middeke H, Korsten FW, Trux FA, Schmieder A, Evers C. 1992. Sequential methotrexate and 5-fluorouracil (FU) vs. FU alone in metastatic colorectal cancer. Results of a randomized multicenter trial. The Association of Medical Oncology (AIO) of the German Cancer Society. Annals of Oncology 3:539–543.
   PubMedGoogle Scholar
• Hiraoka K, Kimura T, Logg CR, Tai CK, Haga K, Lawson GW, Kasahara N. 2007. Therapeutic efficacy of replication-competent retrovirus vector-mediated suicide gene therapy in a multifocal colorectal cancer metastasis model. Cancer Research 67:5345–5353.
   PubMedGoogle Scholar
• Hoff PM, Cassidy J, Schmoll HJ. 2001. The evolution of fluoropyrimidine therapy: From intravenous to oral. Oncologist 6:S3–11.
   PubMedGoogle Scholar
• Hoshino S, Yamashita Y, Maekawa T, Shirakusa T. 2005. Effects on DNA and RNA after the administration of two different schedules of 5-fluorouracil in colorectal cancer patients. Cancer Chemotherapy and Pharmacology 56:648–652.
   PubMedGoogle Scholar
• Khil MS, Kim JH, Mullen CA, Kim SH, Freytag SO. 1996. Radiosensitization by 5-fluorocytosine of human colorectal carcinoma cells in culture transduced with cytosine deaminase gene. Clinical Cancer Research 2:53–57.
   PubMed Web of Science ®Google Scholar
• Kubota T, Watanabe M, Otani Y, Kitajima M, Fukushiuma M. 2002. Different pathways of 5-fluorouracil metabolism after continuous venous or bolus injection in patients with colon carcinoma: Possible predictive value of thymidylate synthetase mRNA and ribonucleotide reductase for 5-fluorouracil sensitivity. Anticancer Research 22:3537–3540.
   PubMed Web of Science ®Google Scholar
• Lawrence TS, Davis MA, Tang HY, Maybaum J. 1996. Fluorodeoxyuridine-mediated cytotoxicity and radiosensitization require S phase progression. International Journal of Radiation Biology 70:273–280.
   PubMed Web of Science ®Google Scholar
• Liu G, Franssen E, Fitch MI, Warner E. 1997. Patient preferences for oral versus intravenous palliative chemotherapy. Journal of Clinical Oncology 15:110–115.
   PubMed Web of Science ®Google Scholar
• Longley DB, Boyer J, Allen WL, Latif T, Ferguson PR, Maxwell PJ, McDermott U, Lynch M, Harkin DP, Johnston PG. 2002. The role of thymidylate synthase induction in modulating p53-regulated gene expression in response to 5-fluorouracil and antifolates. Cancer Research 62:2644–2649.
   PubMed Web of Science ®Google Scholar
• Looney WB, Schaffner JG, Trefil JS, Kovacs CJ, Hopkins HA. 1976. Solid tumour models for the assessment of different treatment modalities: IV. The combined effects of radiation and 5-fluorouracil. British Journal of Cancer 34:254–261.
   PubMedGoogle Scholar
• McGinn CJ, Kinsella TJ. 1993. The clinical rationale for S-phase radiosensitization in human tumors. Current Problems in Cancer 17:273–321.
   PubMedGoogle Scholar
• McGinn CJ, Lawrence TS. 2001. Recent advances in the use of radiosensitizing nucleosides. Seminars in Radiation Oncology 11:270–280.
   PubMed Web of Science ®Google Scholar
• Miller CR, Williams CR, Buchsbaum DJ, Gillespie GY. 2002. Intratumoral 5-fluorouracil produced by cytosine deaminase/5-fluorocytosine gene therapy is effective for experimental human glioblastomas. Cancer Research 62:773–780.
   PubMed Web of Science ®Google Scholar
• Moertel CG, Frytak S, Hahn RG, O’Connell MJ, Reitemeier RJ, Rubin J, Schutt AJ, Weiland LH, Childs DS, Holbrook MA, et al. 1981. Therapy of locally unresectable pancreatic carcinoma: A randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil: The Gastrointestinal Tumor Study Group. Cancer 48:1705–1710.
   PubMed Web of Science ®Google Scholar
• Moertel CG, Childs DS, Reitemeier RJ, Colby MY, Holbrook MA. 1969. Combined 5Fluorouracil and supervoltage radiation therapy of unresectable gastrointestinal cancer. The Lancet 2:3.
   Google Scholar
• Mori A, Bertoglio S, Guglielmi A, Aschele C, Bolli E, Tixi L, Rosso R, Sobrero A. 1993. Activity of continuous-infusion 5-fluorouracil in patients with advanced colorectal cancer clinically resistant to bolus 5-fluorouracil. Cancer Chemotherapy and Pharmacology 33: 179–180.
   PubMedGoogle Scholar
• Mosconi S, Cascinu S, Zaniboni A, Catalano V, Giordani P, Beretta GD, Martignoni G, Pancera G, Baldelli AM, Poletti P, et al. 2000. The value of oxaliplatin in combination with continuous infusion +/+ bolus 5-fluorouracil and levo-folinic acid in metastatic colorectal cancer progressing after 5FU-based chemotherapy: A GISCAD (Italian Group for the Study of Digestive Tract) cancer phase II trial. Tumori 86:465–469.
   PubMedGoogle Scholar
• Nord LD, Martin DS. 1991. Loss of murine tumor thymidine kinase activity in vivo following 5-fluorouracil (FUra) treatment by incorporation of FUra into RNA. Biochemical Pharmacology 42: 2369–2375.
   PubMedGoogle Scholar
• Nord LD, Stolfi RL, Martin DS. 1992. Biochemical modulation of 5-fluorouracil with leucovorin or delayed uridine rescue. Correlation of antitumor activity with dosage and FUra incorporation into RNA. Biochemical Pharmacology 43:2543–2549.
   Google Scholar
• O’Connell MJ, Martenson JA, Wieand HS, Krook JE, Macdonald JS, Haller DG, Mayer RJ, Gunderson LL, Rich TA. 1994. Improving adjuvant therapy for rectal cancer by combining protracted- infusion fluorouracil with radiation therapy after curative surgery. New England Journal of Medicine 331:502–507.
   PubMed Web of Science ®Google Scholar
• Pardee AB. 1989. G1 events and regulation of cell proliferation. Science 246:603–608.
   PubMed Web of Science ®Google Scholar
• Seifert P, Baker LH, Reed ML, Vaitkevicius VK. 1975. Comparison of continuously infused 5-fluorouracil with bolus injection in treatment of patients with colorectal adenocarcinoma. Cancer 36:123–128.
   PubMed Web of Science ®Google Scholar
• Smalley SR, Kimler BF, Evans RG. 1991. 5-Fluorouracil modulation of radiosensitivity in cultured human carcinoma cells. International Journal of Radiation Oncology Biology Physics 20:207–211.
   PubMedGoogle Scholar
• Sobrero AF, Aschele C, Bertino JR. 1997. Fluorouracil in colorectal cancer – a tale of two drugs: Implications for biochemical modulation. Journal of Clinical Oncology 15:368–381.
   PubMed Web of Science ®Google Scholar
• Stephens LC, Ang KK, Schultheiss TE, Milas L, Meyn RE. 1991. Apoptosis in irradiated murine tumors. Radiation Research 127:308–316.
   PubMed Web of Science ®Google Scholar
• Tepper JE, O’Connell MJ, Petroni GR, Hollis D, Cooke E, Benson AB 3rd, Cummings B, Gunderson LL, Macdonald JS, Martenson JA. 1997. Adjuvant postoperative fluorouracil-modulated chemotherapy combined with pelvic radiation therapy for rectal cancer: Initial results of intergroup 0114. Journal of Clinical Oncology 15: 2030–2039.
   PubMed Web of Science ®Google Scholar
• Trump DL, Egorin MJ, Forrest A, Willson JK, Remick S, Tutsch KD. 1991. Pharmacokinetic and pharmacodynamic analysis of fluorouracil during 72-hour continuous infusion with and without dipyridamole. Journal of Clinical Oncology 9:2027–2035.
   PubMedGoogle Scholar
• Vallerga AK, Zarling DA, Kinsella TJ. 2004. New radiosensitizing regimens, drugs, prodrugs, and candidates. Clinical Advances in Hematology and Oncology 2:793–805.
   PubMedGoogle Scholar
• van Groeningen CJ, Pinedo HM, Heddes J, Kok RM, de Jong AP, Wattel E, Peters GJ, Lankelma J. 1988. Pharmacokinetics of 5-fluorouracil assessed with a sensitive mass spectrometric method in patients on a dose escalation schedule. Cancer Research 48: 6956–6961.
   PubMed Web of Science ®Google Scholar
• Wei S, Ageron-Blanc A, Petridis F, Beaumatin J, Bonnet S, Luccioni C. 1999. Radiation-induced changes in nucleotide metabolism of two colon cancer cell lines with different radiosensitivities. International Journal of Radiation Biology 75:1005–1013.
   PubMedGoogle Scholar
• Withers HR, Taylor JM, Maciejewski B. 1988. The hazard of accelerated tumor clonogen repopulation during radiotherapy. Acta Oncologica 27:131–146.
   PubMed Web of Science ®Google Scholar
• Woolley PV, Ayoob MJ, Smith FP, Lokey JL, DeGreen P, Marantz A, Schein PS. 1985. A controlled trial of the effect of 4- hydroxypyrazolopyrimidine (allopurinol) on the toxicity of a single bolus dose of 5-fluorouracil. Journal of Clinical Oncology 3:103–109.
   PubMedGoogle Scholar